CervoMed Inc.
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of th… Read more
CervoMed Inc. (CRVO) - Total Liabilities
Latest total liabilities as of September 2025: $4.60 Million USD
Based on the latest financial reports, CervoMed Inc. (CRVO) has total liabilities worth $4.60 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CervoMed Inc. - Total Liabilities Trend (1998–2024)
This chart illustrates how CervoMed Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CervoMed Inc. Competitors by Total Liabilities
The table below lists competitors of CervoMed Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
New Peoples Bankshares Inc
PINK:NWPP
|
USA | $831.20 Million |
|
EuroDry Ltd
NASDAQ:EDRY
|
USA | $103.13 Million |
|
Kobay Tech Bhd
KLSE:6971
|
Malaysia | RM255.47 Million |
|
First Phosphate Corp.
OTCQB:FRSPF
|
USA | $1.06 Million |
|
E& Corporation CO. LTD
KQ:066980
|
Korea | ₩95.85 Billion |
|
Hexagon Purus ASA
PINK:HPURF
|
USA | $2.85 Billion |
Liability Composition Analysis (1998–2024)
This chart breaks down CervoMed Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CervoMed Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CervoMed Inc. (1998–2024)
The table below shows the annual total liabilities of CervoMed Inc. from 1998 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.88 Million | +49.45% |
| 2023-12-31 | $2.60 Million | -80.27% |
| 2022-12-31 | $13.16 Million | +349.35% |
| 2021-12-31 | $2.93 Million | +0.42% |
| 2020-12-31 | $2.92 Million | -29.65% |
| 2019-12-31 | $4.14 Million | +59.98% |
| 2018-12-31 | $2.59 Million | -47.30% |
| 2017-12-31 | $4.92 Million | -40.77% |
| 2016-12-31 | $8.30 Million | +258.02% |
| 2015-12-31 | $2.32 Million | -49.75% |
| 2014-12-31 | $4.61 Million | -61.17% |
| 2013-12-31 | $11.88 Million | -43.03% |
| 2012-12-31 | $20.85 Million | +5.99% |
| 2011-12-31 | $19.68 Million | +254.17% |
| 2010-12-31 | $5.56 Million | +46.60% |
| 2009-12-31 | $3.79 Million | -23.03% |
| 2008-12-31 | $4.92 Million | -35.30% |
| 2007-12-31 | $7.61 Million | +5222.53% |
| 2006-12-31 | $142.96K | +50.70% |
| 2005-12-31 | $94.86K | -99.51% |
| 1999-12-31 | $19.41 Million | +49.31% |
| 1998-12-31 | $13.00 Million | -- |